Journal of psychopharmacology (Oxford, England)
June 1, 2015
Qing Chang, Taleen Hanania, Deborah C Mash et al.
26 citations
Noribogaine, a drug that acts on opioid receptors, nicotinic receptors, and serotonin transporters, was tested for its ability to reduce nicotine self-administration in adult male rats. After training to self-administer nicotine intravenously, rats received oral doses of noribogaine (12.5, 25, or 50 mg/kg), vehicle, varenicline, or saline. Noribogaine dose-dependently decreased nicotine self-administration by up to 64% compared to saline-treated levels, matching the effectiveness of 1.7 mg/kg varenicline. At the highest dose, noribogaine reduced food pellet self-administration by only 23%, indicating greater specificity for nicotine. The findings suggest noribogaine may be a promising treatment for nicotine dependence.
Pharmacology, biochemistry, and behavior
February 1, 2025
Erin A Clark, Lien Wang, Taleen Hanania et al.
5 citations
Activating the 5-HT1B receptor with the drug CP-94253 produces rapid and sustained antidepressant-like effects in rodents, similar to ketamine. In mice, CP-94253 reduced immobility in the forced swim test and showed a strong antidepressant signature in a behavioral screening platform. Effects lasted at least 24 hours after a single dose in both naive rats and those receiving chronic interferon alpha treatment. The drug also enhanced hippocampal long-term potentiation measured 24 hours later. In mice subjected to chronic social defeat stress, antidepressant-like effects appeared within 1 hour in the tail suspension test and within 24 hours in the sucrose preference test.
The FASEB Journal
April 1, 2015
Émeline L. Maillet, Qing Chang, Nicolas Milon et al.
Noribogaine, a drug that acts on opioid receptors, nicotinic receptors, and serotonin transporters, was tested for its effects on nicotine dependence. It inhibited several types of nicotinic acetylcholine receptors, including α3β4 and α7. In a rat model of nicotine self-administration, noribogaine dose-dependently reduced nicotine intake by up to 64% compared to saline-treated rats, an effect comparable to the approved smoking cessation drug varenicline. These results suggest noribogaine may have potential for treating smoking cessation, substance abuse, and anxiety disorders.